2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Stomach Neoplasms
6
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Adenocarcinoma
2
Triple Negative Breast Neoplasms
1
Squamous-Cell Non-Small-Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Gastrointestinal Neoplasms
1
GastroEsophageal Cancer
1
Gastric or Gastroesophageal Cancer
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
1
bemarituzumab
1
Paclitaxel
1
Docetaxel
1
Carboplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous-Cell Non-Small-Cell Lung Cancer
×
bemarituzumab
×
Clear all
NCT05267470
2025-03-25
FORTITUDE-201
Amgen
Phase 1
Terminated
74 enrolled
22 charts